Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.51 |
| ▸ | PREP | P48147 | 9/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665308 | 1.00 | DPP4 (0.51) | DPP4PREPDPP7DPP8DPP9 | |
| SCHEMBL665317 | 0.98 | DPP4 (0.53) | DPP4PREPDPP7DPP8DPP9 | |
| SCHEMBL666152 | 0.97 | DPP4 (0.49) | DPP4PREPDPP7DPP8DPP9 | |
| SCHEMBL6404619 | 0.88 | NPC1 (0.47) | DPP4PREP | |
| SCHEMBL663417 | 0.88 | NPC1 (0.47) | DPP4PREP | |
| SCHEMBL664742 | 0.86 | DPP4 (0.46) | DPP4PREPDPP7 | |
| SCHEMBL6829857 | 0.86 | DPP4 (0.46) | DPP4PREPDPP7 | |
| SCHEMBL664051 | 0.85 | DPP4 (0.45) | DPP4PREPDPP7DPP8DPP9 | |
| SCHEMBL666993 | 0.83 | DPP4 (0.52) | DPP4PREPDPP7DPP8DPP9 | |
| SCHEMBL875490 | 0.83 | DPP4 (0.63) | DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314884-B2 | non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile | HOFFMANN-LA ROCHE INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885PREP 99/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.